Spyral htn-on med study shows significant, consistent, long-term blood pressure lowering effect at two years

Company commits to advancing clinical data for symplicity™ with the spyral gemini clinical trial and expansion of the gsr-define clinical trial galway, ireland and washington , oct. 28, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced new, long-term data from its spyral htn-on med clinical trial that showed subjects who underwent radiofrequency renal denervation with the symplicity™ spyral renal denervation (rdn) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (abpm), and office-based systolic blood pressure (osbp) compared to sham patients at two years. the data were presented as a part of the 2024 transcatheter cardiovascular therapeutics conference (tct).
MDT Ratings Summary
MDT Quant Ranking